New drug approvals bring new treatment options and potential market opportunities. But what do they mean for companies planning their next generic or biosimilar development program?
October 2026 had two important FDA approvals. Hovilpri (pritelivir) was approved for difficult-to-treat herpes simplex virus (HSV) infections and Hibsago (bepirovirsen) for chronic hepatitis B. Both drugs introduce new treatment approaches.
Let’s take a quick look at their mechanisms and clinical trial results.
1. Hovilpri (pritelivir): A new treatment for difficult-to-treat HSV infections
Hovilpri (pritelivir) is approved for immunocompromised adults with skin or mucosal lesions caused by herpes simplex virus (HSV) that have not responded to commonly used treatments such as acyclovir, valacyclovir, or famciclovir.
How does it work?
Pritelivir belongs to a class of drugs called helicase-primase inhibitors. It blocks an enzyme that HSV needs to copy its DNA and multiply. Unlike commonly used antiviral drugs, it works through a different mechanism. This makes it an important treatment option for patients whose infections do not respond to existing medicines.
It is the first FDA-approved HSV treatment with a new mechanism of action in nearly 30 years.
What did the clinical trials show?
In the Phase 3 PRIOH-1 trial, 63% of patients treated with pritelivir had complete healing of their lesions by day 28, compared with 34% of patients receiving other treatments.
The global antiviral drugs market is estimated at $63.6 billion and is projected to reach approximately $89.4 billion.
2. Hibsago (bepirovirsen): A new approach to chronic hepatitis B
Hibsago (bepirovirsen) is approved for certain adults with chronic hepatitis B (CHB) who do not have cirrhosis. It is used along with their existing hepatitis B antiviral treatment. It is the first antisense oligonucleotide (ASO) therapy approved by the FDA for chronic hepatitis B.
How does it work?
Bepirovirsen targets the genetic instructions that the hepatitis B virus uses to multiply and produce viral proteins. By breaking down these instructions, it helps reduce the amount of virus and hepatitis B surface antigen in the body.
What did the clinical trials show?
In the Phase 3 B-Well 1 and B-Well 2 trials, 19% of patients maintained control of the virus 24 weeks after stopping all hepatitis B treatment. No patients in the placebo group achieved the same result.
The bepirovirsen market is estimated at $36.04 million and is projected to reach approximately $2.12 billion.
Why Early Comparator Drug Sourcing Matters
New drug approvals can create opportunities for generic and biosimilar development. But these programs need access to the right reference listed drug or comparator drug. These products are used for drug testing, formulation development, and bioequivalence or comparative studies.
However, newly approved drugs can be difficult to source. Initial supplies may be limited, and distribution may be restricted. For example, Hovilpri is not expected to reach the US market until later in 2026. Waiting until the development or filing stage to arrange sourcing can lead to delays. Planning early gives your team more time to secure the required products and supporting documentation.
At Spring Bio Solution, we support generic and biosimilar development programs through comparator drug sourcing, including complex and specialty products. Our shipments are traceable and supported by Pedigree Certificates.
October 2026 FDA Approvals at a Glance
| Drug | Approval Date | Drug Class | Approved Use | Current Market Estimate | Projected Market |
| Hibsago (bepirovirsen) | 20 Oct 2026 | Antisense oligonucleotide (ASO) | Chronic hepatitis B in certain adults without cirrhosis | $36.04 million | $2.12 billion |
| Hovilpri (pritelivir) | 9 Oct 2026 | Helicase-primase inhibitor | Difficult-to-treat HSV infections in immunocompromised adults | $63.6 billion (antiviral drugs market) | $89.4 billion (antiviral drugs market) |
Track New Drug Opportunities on NCE Grid
Keeping track of new FDA approvals, exclusivity periods, and first-to-file dates can help pharmaceutical companies plan their next development steps.
NCE Grid brings this information together in one place. Explore Hovilpri, Hibsago, and other newly approved drugs to stay informed about upcoming opportunities.
To track recent FDA approvals, explore NCE Grid.
Planning your next generic or biosimilar development program?
Get in touch with Spring Bio Solution for your comparator drug sourcing requirements.
Stay tuned for the November 2026 FDA Drug Approval Report.




